In the nine-month study of about 475 patients, dalcetrapib raised HDL levels by 31% compared with placebo. It did so without increasing blood pressure or impeding blood flow through the blood vessels.
The findings should ease safety concerns about HDL-boosting drugs that were raised when dalcetrapib's predecessor, torcetrapib, was shown to increase blood pressure and raise the risk of heart attacks and death from heart disease."
email: info@als-alexander.org or interalex2@gmail.com
No comments:
Post a Comment